Jianfeng Group Pro 2015-028 (Announcement of Resolutions of the 5th Session of the 9th Board of Directors)
Release time:
2020-08-05
Securities Abbreviations: Jianfeng Group Securities Code: 600668 No.: Pro 2015-028
Bond Abbreviations: 13 Peak 01 Bond Code: 122227
Bond Abbreviations: 13 Peak 02 Bond Code: 122344
Zhejiang Jianfeng Group Co., Ltd.
Announcement of the Fifth Session of the Ninth Board of Directors
The Board of Directors and all directors of the Company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and shall bear individual and joint liabilities for the authenticity, accuracy and completeness of its contents .
1. Board Meeting
(I) The convening and convening of this board meeting complies with relevant laws, regulations and the relevant provisions of the company's Articles of Association.
(II) 2015# On October 19, 38, the company issued the notice of the board meeting by fax, e-mail and personal service.
(III) 2015# On October 30, 42, the board meeting was held by means of a communication vote.
(IV) 9directors who should attend this board meeting and 9 directors who actually attended the meeting.
2. Board Meeting Review1
, "Company 2015 Third Quarter Report"
After review and voting, the Board of Directors passed the "Company 2015Third Quarter Report".
Voting result: 9votes in favor, 0 votes against and 0 abstentions.
Company 2015Third Quarter Report is available on the Shanghai Stock Exchange website (www.sse.com.cn).
2, Proposal
to Participate in the Relocation of Jinhua Maternal and Child Health Hospital According to the Notice of the General Office of the State Council on Further Encouraging and Guiding Social Capital to Set up Medical Institutions and other relevant policies. According to the company's strategic policy, combined with the needs of the development of the company's pharmaceutical business sector, the company intends to apply to relevant departments to participate in the relocation of Jinhua Maternal and Child Health Hospital.Voting result: 9
votes in favor, 0 votes against, 0 abstentions. For details of
, please refer to the Announcement on Participating in the Relocation of Jinhua Maternal and Child Health Hospital (P.2015 -029).
3, Proposal
on Subsidiary Construction of Modern Pharmaceutical Logistics Center The Board of Directors agreed that subsidiary Jinhua Pharmaceutical Co., Ltd. would invest 66.47 million yuan to build a modern pharmaceutical logistics center in accordance with the requirements of the new GSP for pharmaceutical circulation enterprises on the basis of the land, factory building and other related assets of 599Jinxing South Street, Jinhua City.
Voting Result: 9votes in favor, 0 votes against, 0 abstentions.
4, Proposal on Adding Members of Special Committees of the Board of Directors # The 100 meeting agreed to add Mr. Huang Conyun as a member of the Audit Committee, Remuneration and Evaluation Committee, and Nomination Committee of the 9th Board of Directors of the company. Chairman of the Nomination Committee.
voting result: 9
votes in favor, 0 votes against and 0 abstentions.is hereby announced.
Zhejiang Jianfeng Group Co., Ltd.
Board of Directors
October 30, 2015
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page